Aimmune Therapeutics Inc. | Key People and Executives
Jayson Donald Alexander Dallas
President, Chief Executive Officer & Director
Mark T. Iwicki
Independent Director
Kathryn E. Falberg
Independent Director
Stacey Denenberg Seltzer
Independent Director
Patrick G. Enright
Independent Non-Employee Director
Jayson Donald Alexander Dallas
President, Chief Executive Officer & Director
Jeffrey H. Knapp
Chief Operating Officer
Eric H. Bjerkholt
Chief Financial Officer
Daniel C. Adelman
Chief Medical Officer
Brian Vickery
Senior Medical Director
Annette Marcantonio
Vice President-Clinical Operations
Mary M. Rozenman
Senior VP-Corporate Development & Strategy
Susan E. Barrowcliffe
General Manager-Europe & Senior Vice President
Laura G. Hansen
Vice President-Investor Relations
Alison Marquiss
Media Contact
Kenneth F. Boehm
Vice President-Human Resources
Douglas T. Sheehy
Secretary & General Counsel
William Turner
SVP-Global Regulatory Affairs & Quality Assurance
Mark T. Iwicki
Independent Director
Kathryn E. Falberg
Independent Director
Stacey Denenberg Seltzer
Independent Director
Patrick G. Enright
Independent Non-Employee Director
| Address |
8000 Marina Boulevard
Brisbane California 94005
United States
|
|
Employees
|
- |
| Website |
http://www.aimmune.com |
| Updated |
07/08/2019 |
| Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. |
